DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Clobetasol 0.05% ointment
Drug: Mapracorat (ZK 245186, BAY 86-5319)
Drug: Calcipotriene 0.005% ointment
Drug: Prednicarbate 0.25% ointment
Drug: Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment

First Posted Date: 2018-01-16

Last Posted Date: 2018-01-16

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT03399526

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Naproxen sodium and diphenhydramine hydrochloride soft capsules
Drug: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)

First Posted Date: 2018-01-10

Last Posted Date: 2019-03-20

Lead Sponsor: Bayer

Target Recruit Count: 36

Registration Number: NCT03396250

Locations: 🇺🇸
ICON Development Solutions, LLC, San Antonio, Texas, United States

Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2017-12-29

Last Posted Date: 2018-05-15

Lead Sponsor: Bayer

Target Recruit Count: 76

Registration Number: NCT03386825

Locations: 🇧🇪
Belgium, Multiple Locations, Belgium

Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients

Completed

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: Aflibercept (Eylea, BAY86-5321)

First Posted Date: 2017-12-26

Last Posted Date: 2023-06-05

Lead Sponsor: Bayer

Target Recruit Count: 163

Registration Number: NCT03382587

Locations: 🇨🇭
Many Locations, Multiple Locations, Switzerland

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

Completed

Conditions: Nonvalvular Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Vitamin K antagonist (VKA)

First Posted Date: 2017-12-15

Last Posted Date: 2020-08-17

Lead Sponsor: Bayer

Target Recruit Count: 78517

Registration Number: NCT03374540

Locations: 🇺🇸
Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases, Multiple Locations, Washington, United States

A Study to Test Whether Study Drug BAY1128688 Brings Pain Relief to Women With Endometriosis and if so to Get a First Idea Which Dose(s) Work Best

Phase 2

Terminated

Conditions: Endometriosis

Interventions: Drug: BAY1128688
Drug: Placebo

First Posted Date: 2017-12-14

Last Posted Date: 2019-10-03

Lead Sponsor: Bayer

Target Recruit Count: 121

Registration Number: NCT03373422

Locations: 🇦🇹
Kepler Universitätsklinikum, Linz, Oberösterreich, Austria
🇦🇹
Medizinische Universität Graz, Graz, Steiermark, Austria
🇦🇹
Landeskrankenhaus - Universitätskliniken Innsbruck, Innsbruck, Austria

and more 64 locations

BAY94-9027 PK Study Comparing to Another Long Acting Product

Phase 1

Completed

Conditions: Hemophilia A

Interventions: Drug: Damoctocog (Jivi, BAY94-9027)
Drug: Elocta

First Posted Date: 2017-12-07

Last Posted Date: 2019-09-09

Lead Sponsor: Bayer

Target Recruit Count: 18

Registration Number: NCT03364998

Locations: 🇧🇬
SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia, Bulgaria

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Warfarin sodium

First Posted Date: 2017-12-02

Last Posted Date: 2019-12-11

Lead Sponsor: Bayer

Target Recruit Count: 16000

Registration Number: NCT03359876

Locations: 🇺🇸
US Truven MarketScan, Whippany, New Jersey, United States

Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam

Phase 1

Completed

Conditions: Biological Availability

Interventions: Drug: Desogestrel/ Cerazette
Drug: Norethindrone/ Noriday
Drug: levonorgestrel/ Microlut
Drug: Dienogest/ Visanne
Drug: Drospirenone, Ethinylestradiol/ Yasmin
Drug: Midazolam/ Midazolam-ratiopharm
Drug: Rifampicin

First Posted Date: 2017-11-27

Last Posted Date: 2020-04-15

Lead Sponsor: Bayer

Target Recruit Count: 68

Registration Number: NCT03353857

Locations: 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
🇩🇪
CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany

Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

Phase 1

Completed

Conditions: Chagas Disease

Interventions: Drug: Nifurtimox (Lampit, BAYA2502)

First Posted Date: 2017-11-22

Last Posted Date: 2019-12-12

Lead Sponsor: Bayer

Target Recruit Count: 48

Registration Number: NCT03350295

Locations: 🇦🇷
FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy